You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
“利巴韋林”概念股全線上漲 江蘇吳中漲停 誠意藥業等多股逼近漲停
格隆匯 02-06 09:47
格隆匯2月6日丨A股市場“利巴韋林”概念股全線上漲,其中,江蘇吳中漲停,誠意藥業、長江健康、海王生物逼近漲停,星湖科技漲近7%,延安必康漲近6%,科倫藥業、萬邦德等也明顯上漲。國家衞健委昨日印發新型冠狀病毒感染的肺炎診療方案(試行第五版)。其中在抗病毒治療部分:增加“目前沒有確認有效的抗病毒治療方法。” 在可試用α-干擾素霧化吸入、洛匹那韋/利托那韋基礎上,增加“或可加用利巴韋林”。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account